FDA OKs Sanofi's follow-on biologic of Lilly's diabetes drug Humalog

(Reuters) – The U.S. Food and Drug Administration said on Monday it approved Sanofi SA’s Admelog as the first follow-on biologic version of Eli Lilly and Co’s fast-acting insulin, Humalog.

Source: Reuters Medical News